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Abstract: Intratumoral heterogeneity (ITH) refers to a subclonal genetic diversity observed within 
a tumor. ITH is the consequence of genetic instability and accumulation of genetic alterations, two 
mechanisms involved in the progression from an early tumor stage to a more aggressive cancer. 
While this process is widely accepted, the ITH of early stage papillary thyroid carcinoma (PTC) is 
debated. By different genetic analysis, several authors reported the frequent occurrence of PTCs 
composed of both tumor cells with and without RET/PTC or BRAFV600E genetic alterations. While 
these data, and the report of discrepancies in the genetic pattern between metastases and the 
primary tumor, demonstrate the existence of ITH in PTC, its extension and biological significance is 
debated. The ITH takes on a great significance when involves oncogenes, such as RET 
rearrangements and BRAFV600E as it calls into question their role of driver genes. ITH is also predicted 
to play a major clinical role as it could have a significant impact on prognosis and on the response 
to targeted therapy. In this review, we analyzed several data indicating that ITH is not a marginal 
event, occurring in PTC at any step of development, and suggesting the existence of unknown 
genetic or epigenetic alterations that still need to be identified.  
Keywords: heterogeneity; thyroid cancer; BRAF 3; RET/PTC; clonality 
 
1. Introduction 
Genomic analysis of cancer samples reveals a complex mutational landscape with vast 
intertumor and intratumoral heterogeneity. Intertumoral heterogeneity refers to genetic and phenotypic 
variants occurring among individuals with the same tumor type. Intratumoral heterogeneity (ITH) 
refers to a subclonal diversity that may be observed within a tumor lesion. Intratumoral genetic 
heterogeneity is a paradigm of carcinogenesis, a process that transforms a tumor into a more 
aggressive cancer through gain of genetic alterations. This process transforms a clonal neoplasm into 
a mass of genetically different subclones that may be intermixed or spatially separated within the 
neoplastic tissue. Tumor subclones are characterized by differential gene expression due to both 
genetic and epigenetic heterogeneity, such as chromosome copy number variations, point mutations, 
genes rearrangements or epigenetic modifications that result in phenotypic diversity and intercellular 
heterogeneity. Interestingly, this intercellular heterogeneity, which may promote the development of 
new subclones, is empowered by genomic instability, which is in turn influenced by cancer treatment 
[1]. 
In human tumors, ITH has been documented by Software Inference methods able to infer 
evolutionary relationships between clonal subpopulations based on variant allele frequencies of 
point mutations and taking into account copy number alterations at the mutated loci [2,3]. According 
to these analysis, ITH is highly variable among tumors of different type. For instance, melanomas are 
Cancers 2020, 12, 383 2 of 15 
 
highly polyclonal tumors (8-10 clones/tumor), whereas thyroid cancer (TC) has a mean low number 
of clones (2-4/tumor) [2]. 
Subclonal genetic alterations may be present only in a fraction of cells of distinct regions within 
the same tumor (spatial heterogeneity), or subclonal genetic alterations of the primary tumor may be 
different from those of subsequent local or distant recurrences of the same patient (temporal 
heterogeneity) [4]. This phenomenon can be clinically relevant because the genetic pattern found in the 
primary tumor that in some cases steers the clinical and therapeutic decisions, may evolve during 
tumor progression, in particular in the regional or distant metastases, also due to the selection 
pressure of treatment [5]. Accordingly, a discordant pattern between the primary and the metastatic 
site has been recorded in several tumors (including lung, melanoma, colorectal, gastric, and breast), 
with a prevalence ranging 0%–49%. Some mutations are found to be private to the primary tumor, 
some private to metastases, and other shared [4,6]. 
ITH is likely to be the consequence of either the presence of two mutations in different clones in 
the primary tumor and to the distant propagation of only one clone, or to the acquisition of a 
secondary event at the metastatic site [7]. In this context, it would be critical to identify the cancer 
cells that have the potential to contribute to disease progression, in order to develop more effective 
cancer therapies. 
In TC, two possible mechanisms underlying ITH were proposed. The hierarchical or cancer stem 
cell (CSC) model proposes that TC arises from the remnants of undifferentiated fetal thyroid cells, 
especially thyroid stem cells. According to the step of differentiation of the stem cell, after genetic 
and epigenetic transformations, phenotypically different cancer cells are generated with different 
degrees of aggressiveness [8–11]. Recently, sphere-growing cells were isolated from primary cultures 
of PTC, which fulfilled the definition of CSC and showed evidence of coordination in controlling 
tumorigenesis and progression [12]. 
The second mechanism is a paradigm of the carcinogenesis and the most accepted theory of 
thyroid tumor development, i.e., the stochastic multistep model, which is based on the theory of 
cancer clonal evolution [13]. This model states that tumor formation is a consequence of genome 
instability within somatic cells, which can lead to the appearance of more aggressive clones able to 
survive the selection pressure of the microenvironment and to outcompete other cells. This may result 
in a genetically homogenous tumor until a new more significant mutation appears. In this model, 
distinct molecular alterations were associated with specific stages that drive progression from well-
differentiated to undifferentiated follicular-derived thyroid carcinomas [14]. A clear example of this 
process is the well demonstrated appearance of mutations, e.g., in TERT, PI3k or p53, in poorly 
differentiated thyroid carcinomas (PDTC) and in anaplastic tumors (ATC), which add themselves to 
pre-existing genetic alterations e.g, BRAF or RAS point mutations [15–18]. Consistently, the 
mutational burden is higher in less differentiated tumors than in differentiated or pediatric tumors 
[19], and associate with a more advanced stage and a worst prognosis [20]. Although the ITH 
developed during the process of dedifferentiation in PDTCs and ATCs is well established, the 
presence of ITH in the first phases of TC progression is a debated topic. The present review reports 
and discuss the data published in the literature related to the impact of ITH in the origin and 
progression of papillary thyroid cancer (PTC), which accounts for almost 80% of all TC cases, and to 
the diagnostic and clinical implications related to this phenomenon. 
2. Intratumoral Heterogeneity in Papillary Thyroid Cancer 
Papillary thyroid cancer is the most frequent endocrine tumor, and has in general a good 
prognosis, though a small fraction shows higher aggressiveness, and cannot be cured by standard 
treatments such as surgery and radioiodine. For these advanced cases, targeted therapies were 
recently developed directed towards either angiogenic pathways or genes known to be involved in 
thyroid carcinogenesis [21]. Somatic mutations in the mitogen-activated protein kinase (MAPK) 
pathway are found in nearly 70% of PTC, being BRAFV600E the most frequent variant. Despite its 
potential clinical relevance, ITH was scantly investigated in PTC, probably due to the low number of 
oncogenes involved, which are frequently mutually exclusive, compared to other cancers [22], such 
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as lung cancer and melanoma, where multiple oncogenes are frequently found to be altered in the 
same tumor at early stages [5]. As an example, subclonal BRAFV600E, the most frequent mutation in 
melanoma, was described in several reports. In particular, single cells genotyping showed BRAFV600E 
heterogeneity within metastatic primary melanomas [23], in melanoma metastases [24], and among 
circulating tumor cells [25]. Similarly, subclonal RAS mutations were described in melanomas, and 
N-RAS and BRAF activating mutations were demonstrated to coexist in the same melanoma in 
different cells [26]. 
Unlike melanoma, PTC is considered to be largely homogeneous, so that a subtype classification 
was proposed according to the mutation detected, i.e., BRAF-like and RAS-like PTC [22]. Extended 
analysis of large series of tumors demonstrated a relatively low overall density of somatic mutations 
that is believed to be the biological basis for the indolent clinical behavior of PTC. Technical issues 
can partly explain the scanty data on ITH in PTC: the genetic pattern of PTCs was mostly investigated 
by the low sensitive sequencing Sanger method and was not to identify mutations present with a low 
allelic frequency [27]. Thyroid tumors consist of neoplastic cells intermingled irregularly with normal 
(connective tissue and vessels) and reactive (stromal and immune) cells, and the ratio between these 
components may vary largely between tumors [28]. Thus, the neoplastic cells content and the allelic 
frequency of the mutated oncogene in a given sample can be extremely low and below the sensitive 
threshold of many analytical methods. Accordingly, in PTC the allelic frequency must be normalized 
for the percentage of tumor cells in the sample, a measurement not always easy to perform [22,29]. 
Indeed, the number of the studies included in the present review which report data on the genetic 
characterization and/or ITH in TC, not evaluating tumor purity [27,30–52] are significantly more 
numerous than those which normalized the data for the percentage of tumor cells [7,20,22,29,53–55]. 
Thus, data on ITH obtained without considering the purity of the tumor must be considered with 
caution. Moreover, it should be underlined that a rigorous method to establish the genetic 
heterogeneity and clonality of cancer should include the evaluation of copy number alteration, too. 
Recent data from the pan genomic characterization of a synchronous FTC, PDTC and ATC showed 
that the cancer cells fraction determination (CCF), which denotes the proportion of cells among all 
cancer cells carrying a specific genetic aberrancy, allows precisely establishing the clonal composition 
of the tumors during the dedifferentiation process [19]. 
More recent methods of genetic analysis, i.e., pyrosequencing, allele-specific locked nucleic acid 
PCR, and next-generation sequencing, made possible a deeper and quantitative analysis of the 
mutational status of tumor samples, providing data in favor of ITH in PTC. Nevertheless, the 
existence and the relevance of subclonality in PTC is still debated since discordant evidence is 
available to date [56]. Moreover, the contribution of intratumoral heterogeneity to thyroid metastatic 
cancers and the clonal relationships between the primary thyroid tumor and lymph node or distant 
metastases are still unknown. 
3. Evidence in Favor of ITH in PTC 
Much evidence has been reported supporting the occurrence of ITH in PTC, either in early or 
advances stages of progression (Table 1). 
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Table 1. Arguments in favor and in contra on the presence of extensive intratumoral heterogeneity 
(ITH) in papillary thyroid cancer. 
Proofs of Extensive ITH Ref. 
1) Heterogeneous presence of a 
mutation documented by genetic 
analysis 
Fusco et al. 2002 [34], Unger et al. 2004 [30], Vasko et al. 2005 [39], Unger et al., 2006 
[31], Zhu et al. 2006 [32], Rhoden et al. 2006 [33], Hieber et al. 2011 [35], Guerra et al. 
2012 [36], Guerra et al. 2012 [57], Xing et al. 2012 [38], Gandolfi et al. 2013 [7], De 
Biase et al. 2014 [29], Kim et al. 2014 [37], Muzza et al. 2015 [40], Finkel et al. 2016 
[53], Colombo et al. 2019 [20], Masoodi et al. 2019 [58] 
2) Heterogeneous presence of 
BRAFV600E by immunodetection 
Gandolfi et al. 2013 [7], De Biase et al. 2014 [29], Dvorak et al. 2014 [41] 
3) Presence of concomitant 
mutations 
Sugg et al. 1999 [50], Wang et al. 2008 [42], Henderson et al. 2009 [45], Guerra et al. 
2012 [57], Landa et al. 2013 [46], Kim et al. 2014 [37], Xing et al. 2014 [43], Guerra et 
al. 2014 [44], Wang et al. 2014 [47], Muzza et al. 2015 [40], Shrestha et al. 2015 [48], 
Rossi et al. 2015 [49], Finkel et al. 2016 [53], Landa et al. 2016 [54], Colombo et al. 
2019 [20], Masoodi et al. 2019 [58] 
4) Discordant mutational status 
between primary site and 
metastases 
Vasko et al. 2005 [39], Oler et al. 2005 [59], Ricarte-Filho et al. 2009 [27], Walts et al. 
2014 [51], Muzza et al. 2015 [40], Le Pennec et al. 2015 [55], Sohn et al. 2016 [60], 
Caňadas-Garre et al. 2016 [61], Melo et al. 2017 [52], Fakhruddin et al. 2017 [62], 
Shifrin et al. 2017 [63], Masoodi et al. 2019 [58], Masoodi et al. 2019 [64], Gawin et al. 
2019 [65] 
Cons of extensive ITH 
1) Heterogeneous presence of a 
mutation documented by genetic 
analysis only in a minority of 
cases 
Cancer Genome Atlas Network 2014 [22], Colombo et al. 2019 [20], Masoodi et al. 
2019 [58] 
3.1. Heterogeneous Presence of a Mutation Documented by Genetic Analysis 
The first evidence of ITH in PTC came from studies evaluating the presence of RET/PTC 
rearrangements. The distribution of RET fusions was investigated by means of different approaches, 
demonstrating to vary in sporadic PTC or in post-Chernobyl PTC cases. The analysis of RET 
rearrangements by interphase fluorescence in situ hybridization (FISH) in 29 adult and 13 childhood 
post-Chernobyl PTCs unveiled that in all positive cases (23 and 10, respectively), the tumors were 
composed of a mixture of cells with and without RET rearrangements [30,31]. This ITH was further 
confirmed by a different research group that analyzed by FISH 14 RET/PTC positive PTC, finding 
nine cases with 50%–86% positive cells and five cases with 17%–35% positive cells [32]. High level of 
recombinant RET/PTC mRNA, a finding that the authors considered compatible with a clonal 
occurrence of the recombination, was observed only in 46% of RET rearrangements-positive adult 
PTC [33]. Interestingly, immunohistochemistry and reverse transcriptase-polymerase chain reaction 
(RT-PCR) analyses performed on RNA extracted after laser capture microdissection, and FISH 
experiments demonstrated the subclonal occurrence of RET/PTC rearrangements not only in PTC but 
also in hyperplastic or adenomatous nodule and even in scattered thyroid cells in Hashimoto’s 
thyroiditis [33,34]. In the study by Zhu et al. different detection methods with different sensitivity 
(standard-and high-sensitivity RT-PCR, real-time Light Cycler RT-PCR, Southern blot analysis, and 
FISH) demonstrated the subclonal or non-clonal occurrence of RET/PTC-1 and -2 in 17 of 65 (26%) 
PTC, while the clonal occurrence was demonstrated only in 9 (14%) tumors [32]. 
In following years, ITH of BRAFV600Ewas demonstrated in PTC by different molecular techniques 
(Table 2). By pyrosequencing analysis, the subclonal or even oligoclonal occurrence of BRAFV600E 
mutation was found to be more frequent than the clonal occurrence [36,57]. BRAFV600E was 
demonstrated in more than 45% of alleles only in a minority of cases, indicating that BRAFV600E 
mutation is frequently an oligoclonal event [57]. This data was confirmed by Gandolfi et al. [7] who 
showed by pyrosequencing in 58 BRAFV600E-positive PTC, an average mutated allele percentage of 
27.44%, with a range between 7.50% and 49.80%. Further demonstration that both BRAFV600E positive 
and negative cells can coexist in classic PTC was achieved by pyrosequencing of 264 manually 
microdissected BRAFV600E-positive tumors in which the mutant allelic frequency ranged 8%–41% of 
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the total BRAF alleles (median, 20%) [37]. Based on these studies, for both RET/PTC and BRAFV600E 
the subclonal occurrence in PTC appears to be something more than a rare event. The demonstration 
that the PTC tumor mass frequently consists of a mixture of few cells bearing mutant BRAF and more 
abundant tumor cells bearing wild-type BRAF was further confirmed after normalization for the 
percentage of tumor cells, and by the analysis of single cells obtained by laser capture [57]. De Biase 
et al. applied the allele-specific locked nucleic acid PCR to 155 PTC to determine the presence of 
BRAFV600E and the allelic frequency after subtraction of non-tumor cells [29]. They observed that 10.6% 
PTCs displayed < 30% of BRAFV600E neoplastic cells, and 45.9% PTCs displayed 30–80% of BRAFV600E 
neoplastic cells. Overall, the 63.8% of PTCs had less than 80% of mutated cells. The heterogeneous 
distribution of BRAFV600E in PTC, indicating subclonality or even oligoclonality, was confirmed in 
subsequent studies by means of next generation sequencing (NGS). The analysis of 30 BRAFV600E-
positive PTC by 454 NGS, revealed a mean and median of BRAFV600E-positive neoplastic cells of 72.3% 
and 83%, respectively [29]. In another study, after the exclusion of non-tumoral cells by means of a 
morphometric analysis, 24% of 49 BRAFV600E positive PTC were found to be subclonal by Ion Torrent-
NGS [53]. These agreeing findings obtained in different laboratories by means of different methods, 
led to hypothesize that this mutation is not always the first transforming genetic event and that it can 
be a secondary event in PTC tumorigenesis [38,39]. More recently, the analysis of the ITH of PTC was 
extended to TERT and RAS genes. After normalization for tumoral cell content, MassARRAY 
genotyping confirmed the finding of the mutations in these two genes at low allelic frequencies in 
some samples, consistent with their presence in a small subset of cancer cells [20,24]. Recent data 
obtained by a multi-region WES approach on 257 PTC tumor tissues showed the presence of a 
subclonal driver alteration in 29% of tumors [58]. 
Table 2. Studies reporting significant BRAFV600E intratumoral heterogeneity by different techniques. 
Technique BRAFV600E Clonal Status  
VE1 Anti-BRAFV600E 
antibody 
Stained and non-stained PTC cells clustered separately or intermingled in the primary 
and in the metastatic lymph nodes. Gandolfi et al. 2013, [7]. 
36% of PTCs displayed < 80% of BRAFV600E positive cells. De Biase et al. 2014, [29]. 
Unspecified percentage of PTC displayed < 15% stained cells. Dvorak et al. 2014, [41] 
Pyrosequencing 
66.5% of BRAFV600E PTCs presented an allelic frequency ranging 5.1%–25%. Guerra et al. 
2012, [57] 
54.9% mean of cells with BRAFV600E in mutation positive PTC. Gandolfi et al. 2013, [7] 
20% median of cells with BRAFV600E in mutation positive PTC. Kim et al. 2014, [37] 
19.4% PTCs had a dual mutation BRAFV600E and RET/PTC, with a BRAF allelic frequency 
ranging 6–37.5%. Guerra et al. 2014, [44] 
Allele-specific locked 
nucleic acid PCR 
10.6% PTCs with < 30% of BRAFV600E neoplastic cells; 45.9% PTCs with 30%–80% of 
BRAFV600E  
neoplastic cells. De Biase et al. 2014, [29] 
Next Generation Sequencing 
72.3% mean of cells with BRAFV600E in mutation positive PTC. De Biase et al. 2014, [29] 
24% of the BRAFV600E PTCs were subclonal. Finkel et al. 2016, [53] 
BRAFV600E was subclonal in 30% primary non-relapse and in 44% primary relapse PTC. 
Masoodi et al. 2019, [58] 
Sequenom MassArray 12.6% of BRAF
V600E PTCs had an allelic frequency lower than 50%. Colombo et al. 2019, 
[20] 
3.2. ITH of BRAFV600E by Immunodetection  
A monoclonal BRAFV600E mutation-specific antibody (VE1) was developed by Capper et al. in 
2011 [66]. The heterogeneous staining described in some melanoma samples in the first report, was 
imputed to necrosis, though in subsequent studies this technical issue was no more reported and this 
antibody was considered a valid tool to investigate the intratumoral distribution of BRAFV600E [66]. In 
a series of 85 PTCs analyzed by immunohistochemistry (IHC) with the VE1 antibody, 37 cases (43.5%) 
displayed more than 80% of stained cells, 39 cases had 30%–80% (45.9%), and nine had less than 30% 
(10.6%) stained cells [29]. In a different laboratory, when stained with the same antibody, 
immunoreactive and non-immunoreactive PTC cells were clustered separately or were intermingled 
in the primary lesions and in the corresponding metastatic lymph nodes [7]. These data indicated 
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that as for the primary lesions, the matched lymph nodes where heterogeneous for the 
BRAFV600Emutation. Contrasting data come from Ghossein et al. who found a homogeneous staining 
in 13/14 PTCs, in 3/3 poorly differentiated TCs, and in 12/14 anaplastic TCs, supporting the concept 
that the BRAFV600E mutation is a clonal event in the majority of TCs while ITH is a rare occurrence 
[67]. IHC with VE1 was employed in many studies to determine its reliability as diagnostic tool, 
though the issue of heterogeneity has not been addressed and, currently, the tumor is considered 
positive when a significant percentage of tumoral cells is stained.  
3.3. Presence of Concomitant Mutations 
In recent years, also thanks to advances in NGS technology, it has become evident that multiple 
mutations can be concomitantly present in the same tumor [68,69]. In the context of PTC, co-
occurrence of mutations, such as BRAFV600E, TERT, RET/PTC and H4/PTEN has been frequently 
documented, indicating that these genetic alterations might coexist in the same tumor [40,42–47]. 
Dual mutation of BRAFV600E and RET/PTC and of BRAFV600E and TERT promoter [37,48,53,54,57] and 
of point mutations and fusions [20] were found to occur in up to 20% PTCs. Although sporadically, 
concomitant occurrence of different RAS mutations or mutations of different RAS isoforms or 
concomitant RAS mutations and RET/PTC rearrangements were reported [49,50]. 
3.4. Discordant Mutational Status Between Primary Site and Metastases 
The multistep/multigene model with a progressive acquisition of new genetic defects is a 
paradigm of carcinogenesis. A discordant mutational status between the primary site and the 
metastases supports this mechanism and it was recorded in several human tumors (including lung, 
melanoma, colorectal, gastric, breast) [4]. In TC, discordant patterns were reported for BRAFV600E, 
TERT, RAS and other mutations [27,39,40,51,52,58–65]. Data related to PTC are reviewed in Table 3. 
In particular, the BRAF mutational status between primary tumor and metastases, mainly loco 
regional, was found to be discordant in up to 50% of cases, by different techniques 
[39,40,51,52,59,61,62]. In a recent study, it was shown that 14/27 TERT mutated primary tumors had 
wild-type TERT lymph node or distant metastases [52]. The loss in the metastases of the BRAF or 
TERT mutation present in the primary site is a very unlikely occurrence, hence these data strongly 
support the ITH of the primary tumors. Additional findings concerning ITH, and clonal relationship 
between primary tumor and metastases come from a case report of an aggressive PTC with matched 
lymphnode and a pleural metastasis. By the analysis of single nucleotide variants, gene fusions, and 
loss of heterozygosity, the authors showed that some of the genetic alterations were ubiquitously 
detected in all the tumor samples from the patient and others were detected only in some tumor 
areas, indicating the presence of several subclones in the neoplastic tissues. Interestingly, the two 
selected areas of the primary tumor and the two selected areas of on regional metastasis presented 
similar genetic profiles, whereas the two selected areas of another regional metastasis had more 
divergent mutations and fusions [55]. Striking heterogeneity was also observed between paired 
primary tumors and metastases in studies done by means of NGS and WES studies [58,60,63,64].  
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Table 3. Mutational status of metastatic sites with respect to corresponding primary papillary thyroid 
cancer. 
Genetic Analysis Metastatic Site Mutational Status with 
Respect to Primary Tumor 
Ref. 
BRAF exon 15 direct sequencing and single-
strand conformational polymorphism 
lymph node  9 concordant/4 discordant  
Oler et al.  
2005 [59] 
BRAF exon 15 direct sequencing lymph node  26 concordant/7 discordant  
Vasko et al.  
2005 [39] 
BRAF exon 15 and TERT promoter mutation 
direct sequencing 
lymph node 9 concordant/3 discordant 
Muzza et al. 2015 
[40] 
BRAF exon 15 direct sequencing lymph node 23 concordant/2 discordant  
Walts et al.  
2014 [51] 
Target NGS, TERT promoter mutation direct 




5 concordant/2 discordant 
2 concordant 
Sohn et al.  
2016 [60] 
BRAF exon 15 and N-RAS exon 2 and 3 
direct sequencing 
lymph node and 
distant metastases  
14 concordant/15 discordant 
Caňadas-Garre et 
al. 2016 [61] 
BRAF, K- and N-RAS mutations by reverse 
hybridization 
lymph node 38 concordant/5 discordant 
Fakhruddin  
et al. 2017 [62] 
Target NGS lymph node 13 concordant/8 discordant Shifrin et al. 2017 
[63] 
BRAF exon 15, N-RAS exon 2 and 3, TERT 
promoter mutation direct sequencing 












7 concordant/2 discordant* 
2 concordant/1 discordant* 
1 discordant* 
1 discordant* 
Masoodi et al. 
2019 [64] 
WES local relapse 4 concordant/1 discordant 
Masoodi et al. 
2019 [58] 
Mass spectrometry imaging lymph node discordant 
Gawin et al. 2019 
[65] 
Legend: *for likely pathogenic cancer genes. 
The contribution of ITH to thyroid metastatic cancers still needs to be more studied and clarified, 
though the finding of genetic heterogenous PTCs allows proposing hypotheses related to thyroid 
oncogenesis and progression (Figure 1). 
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Figure 1. Hypotheses related to papillary thyroid cancer oncogenesis and progression (see text). (A) 
A known mutation occurs in the thyroid follicular cell and leads to the development of the tumor. (B 
and C) The tumor is established by a genetic driver (known or unknown). A second genetic event is 
acquired either in the same cell (B) or in a different cells (C) and transmitted with a sub-clonal 
distribution at the primary site. (D)A second genetic event is acquired at the metastatic site. 
A) A known mutation occurs in the thyroid follicular cell and leads to the development of the 
tumor. Thereafter, the mutation is clonally distributed in all the tumor cells at the primary site and 
propagated to all the metastases developed during tumor progression. Primary tumor and 
metastases are clonal and the driver gene is detectable in both. This scenario is likely to be extremely 
frequent for PTC. 
B) The tumor is established by the transformation of a thyroid cell by a genetic driver (known or 
unknown). A second genetic event is acquired and transmitted to a subset of tumor cells at the 
primary site (sub-clonal distribution). The second genetic event can occur either in the same cell or in 
a different cell. This heterogeneous pattern can lead to the development of metastases with different 
genetic assets, namely cells with a double oncogenic expression or cells with monogenic expression 
intermingled with cells with a double oncogenic expression. 
C) A second genetic event is acquired at the metastatic site, either in the same cell or in different 
cells. The acquisition of a second event is predicted to increase the growth potential leading to the 
development of a clinically evident metastasis.  
4. Evidence Limiting the Impact of ITH In PTC 
While large data support the IHT in PTC, its biological significance and clinical impact is 
debated. In some studies, the occurrence of ITH has been called into question or it is considered a 
limited or extremely limited phenomenon in PTC. With the Cancer Genome Atlas (TCGA) project, 
whole genome DNA of a large PTC cohort was examined by NGS [22]. This study reported somatic 
mutations in 83% and gene fusions in 13% of cases, mostly affecting the RAS/RAF/MAPK pathway. 
With very few exceptions, all mutations had an allelic frequency below 50%. However, subtracting 
the non-cancer cells estimated by a computational method that uses a pre-computed statistical 
models of recurrence cancer karyotypes [70], the major driver mutations documented (BRAFV600E, 
RAS mutations, and RET/PTC) were present in the majority of tumor cells with only very few 
exceptions. These findings led the authors to conclude that the tumors were largely clonal and that 
oligoclonality or polyclonality with respect to these oncogenes is a phenomenon limited to a few PTC 
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cases. However, it is dutiful to highlight that FISH and PCR-based analysis are concordant assigning 
to ITH a significant impact in PTC, while NGS analysis are discordant. More recently, we analyzed a 
large cohort of 208 PTC by MassARRAY, and we calculated the allelic frequencies of BRAFV600E and 
RAS mutations by subtracting non-tumor cells. The majority of cases had an allelic frequency of the 
mutated allele consistent with a monoclonal origin of the tumor, suggesting the occurrence of ITH in 
a small, though not negligible, subset of tumors (8%) [20]. 
5. Heterogeneity of Thyroid Cancer: Clinical and Therapeutic Implications 
5.1. Spatial Heterogeneity 
Impact on clinical behavior: some studies showed that mutation density highly correlates with 
aggressive histologic features and risk of recurrence [20,22]. Although the association of mutation 
density with worst outcome was not found in one study including cases with high-recurrence risk 
[71], most studies report that patients with dual mutations are associated with an older age at 
diagnosis and a worst outcome, suggesting that tumors with multiple mutations undergo a positive 
selection and are more aggressive [40,43–45,47]. Of note, TERT mutations were found to be mainly 
subclonal in PTCs, whereas they were clonal in poorly differentiated and anaplastic tumors, 
consistent with a positive selection during tumor evolution [54]. As far as BRAFV600Econcerns, 
subclonal mutations were associated with smaller PTC tumors [29,37,53,57,72], lower extrathyroidal 
extension [37,53]and lower recurrence rate [57], while other studies did not report significant 
association with disease progression [7]. In contrast, Masoodi et al. showed that subclonal mutations 
were significantly higher in relapsed PTCs and that cases with high burden of subclonal mutations 
were associated with distant metastasis and increased risk of relapse or death [58]. 
Impact on diagnosis: as stated for other tumors [73], the presence of molecular heterogeneity 
highlights the importance of sampling multiple areas of the same tumor to better ascertain the range 
of genomic alterations characterizing its progression. In a recent study, it was found that the 23.1% 
of the somatic mutations found in a large PTC series were not identified in all regions of the tumor, 
revealing that ITH limits the diagnostic value of single diagnostic biopsy sample [58]. Particularly in 
advanced TCs, the heterogeneous presence of genomic alterations may impair patient genotyping 
and subsequent prognostic classification and targeted therapy. Moreover, some mutations, despite 
their very low allelic frequencies in the primary tumor, can be responsible for the development of 
metastases, indicating the need for highly sensitive diagnostic tools to obtain a full genetic 
characterization. 
Impact on treatment: ITH could have a significant impact on prognosis and treatment response 
and may influence the best and targeted therapeutic strategy, especially in the era of personalized 
medicine [5]. Indeed, the genetic pattern found in the primary tumor that in some cases directed the 
clinical and therapeutic decisions, may be not representative of the variation within a tumor as a 
whole, and may evolve during tumor progression, also due to the selection pressure of treatment [4]. 
Consequently, for many tumors, combinations of targets-based drugs will likely be necessary to 
control the tumor growth. 
5.2. Temporal Heterogeneity 
The different subclones are predicted to have different resistance mechanisms to treatment. If 
they are all sensitive to the initial treatment, the tumor will be eradicated. Cancer relapse can be due 
to the progressive enrichment with time of drug resistant cancer cells already present in the 
heterogeneous cancer cell population. Indeed, it is predicted that a fraction of cells with stem cell 
properties and probably also a fraction of adult cells within the heterogeneous population are drug 
resistant, able to survive to treatment and expanding over time [74], as shown for some cancers such 
as lung [75]. It is worth mentioning that temporal heterogeneity derives also from the progressive 
increase of the mutational burden during the de-differentiation process [15–18]. The best way to 
identify the presence of different subclones, is to submit the primary tumor to an ultra-deep sequence 
which allows identifying all the mutated clones, in order to start a treatment directed by the 
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characteristics of the dominant clone as well as the rare resistance clones, with a combination of 
therapies to eradicate all clones. Nevertheless, this option is rarely applied, especially for TC which 
is a tumor well curable in the vast majority of cases. 
Interesting insights come from a recent report of an acquired KRAS mutation that developed 
during treatment with BRAF and MEK inhibition in a patient with a BRAF-mutated PTC. The KRAS 
mutation was detected at the time of progression in the peripheral blood, too [76]. This last finding 
demonstrates that resistant mutations can be documented even with non-invasive methods, such as 
plasma DNA or circulating tumor cells [77]. 
Additional tools to identify resistant subclones, imply their analysis in cellular systems, which 
also allows the testing for different and possible novel therapeutic options. As far as TC concerns, 
Antonello et al. expanded a sub-population of cells with primary resistance to vemurafenib and 
found that they harbor amplification of chromosome 5 and mutations in RBM genes which are crucial 
for genome stability during cell division [78]. A combined therapeutic approach using BRAFV600Eand 
CDK4/6 inhibitors was able to induce apoptosis in both naïve and vemurafenib-resistant cells, 
indicating that this combined therapy could be tested in a clinical trial of advanced TC patients.  
6. Conclusions 
Intratumoral genetic heterogeneity identify a phenomenon by which a neoplasm harbors 
genetically different subclones that may be intermixed or spatially separated. Importantly, the 
number of genomic alterations spontaneously increases with tumor progression and can evolve in 
response to treatments. Different types of cancer are characterized by different subclonal complexity, 
sometimes with a high number of subclones such as melanoma, and other times showing a low 
number such as the case of thyroid cancer. The existence of the ITH is well accepted for advanced 
PTC, while it is a debated issue for PTCs in the early stage of progression. Several data presented in 
this review indicate that ITH is not a marginal event that can occur in PTC at any step of development, 
including early stage PTC. Furthermore, the demonstration of ITH of BRAF and RAS mutations and 
RET/PTC rearrangements highlights the existence of unknown genetic or epigenetic alterations that 
still need to be identified. 
The ITH of BRAF and RAS mutants and RET/PTC rearrangements in early stage PTC, call into 
question their role of driver mutations and initiators of thyroid carcinogenesis. In a stochastic model 
of multi-step carcinogenesis, the coexistence of BRAF mutation negative and positive subclones 
entails that these oncogenes are generated succeeding other unidentified genetic alterations which 
have the role of initiators. In the cancer stem cell (CSC) model, a small subpopulation of CSCs that 
can self-renew and differentiate to produce phenotypically diverse cancer cells acquires initiating 
mutations, with BRAF, RAS and RET/PTC alterations developing later, and involving only a cellular 
subpopulation.  
Based on the present knowledge of this topic, the definition of the TC genetic background must 
consider the existence of either heterogeneity or multiple mutations with different allelic percentage. 
In this context, benefits will come from NGS techniques (especially whole genome sequencing) since 
these tools allow better appreciating clonal cancer cell fractions of important mutations mostly 
because of the high-resolution CNV analyses. It is also well known that the presence of intra-tumor 
heterogeneity is the cause for relapsing after the therapy, which effectively eliminated the 
competition of the major clone, leaving minor subclones free to expand. The assessment of such 
complexity, for instance by the analysis of paired primary and metastatic samples from the same 
patient to acquire insights into clonality and subclonality patterns of genomic events, is mandatory 
for the further development of personalized medicine in TC. 
Since novel generation compounds highly selective for a specific genetic alteration are currently 
on trial, the assessment of the genetic pattern of malignant tumors, including advanced TC, is 
definitely needed. The genetic evaluation should consider the identification of the percentage of 
mutated cells, too, by normalization for the non-tumoral cell content of the neoplastic mass, since it 
is predictable that different allelic frequencies of a given mutation could correlate with the response 
to treatment. 
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